FAQ: Capitalization and amortization of R&D costs under new section 174 rules

Posted on March 14th, 2024

It’s crucial to distinguish current assets from non-current assets in the context of research and development capitalization. Assets capitalized under IFRS could potentially lead to a higher value of non-current assets on the balance sheet, as opposed to immediate expensing under US GAAP. In terms of R&D cost accounting, efforts continue to understand and possibly reconcile the different treatments.

What delineates the treatment of research costs under IFRS compared to US GAAP?

• Any ongoing R&D projects acquired, known as in-process research and development (IPR&D), are not expensed.
• When expenses are spread out over time, it’s simpler to take on other projects due to the reduction in upfront R&D costs.
• Because of this, until the IRS issues further guidance, it is reasonable to continue to rely on guidance under section 174 as it existed before amendments by the TCJA.
• The figure disclosed should represent the total of all costs included under the scope of ASC 730, such as salaries, materials, and depreciation on assets used in R&D.

However, it can provide tax benefits in the long run as the asset is amortized. Thus, except for some relatively minor exceptions, all research and development costs are expensed as incurred according to U.S. The probability for success is not viewed as relevant to this reporting. The total cost incurred each period for research and development appears on the income statement as an expense regardless of the chance for success. The accounting treatment of research and development costs also influences the reporting of liabilities and liquidity. Under IFRS, if development costs are capitalized, they may result in the recognition of non-current liabilities, such as deferred tax liabilities due to temporary differences arising from the capitalization of these costs.

Companies must provide robust documentation and demonstrate a thorough understanding of impairment indicators to withstand scrutiny from auditors. Choosing whether to currently deduct or to amortize R&D typically depends on an entity’s projections of taxable income, on whether net operating loss carryovers might expire unused, and on other tax circumstances. In some cases, the at-risk rules of IRC section 465 or passive loss limits of IRC section 469 may be applicable.

Viewed from that angle, this one resource provides you with a roadmap to resolving the many varied issues that can arise with R&D activities. KPMG has market-leading alliances with many of the world’s leading software and services vendors. KPMG’s multi-disciplinary approach and deep, practical industry knowledge help clients meet challenges and respond to opportunities.

Specifically, in the context of research and development (R&D) costs, U.S. Companies must navigate complex accounting environments when dealing with research and development (R&D) costs, particularly when looking at the contrast between U.S. Differences in the treatment of these costs can have significant practical implications for financial reporting and operations. This divergence in accounting treatment can lead to differences in the financial statements presented to stakeholders, including the Securities and Exchange Commission (SEC) for U.S. companies.

Improved Financial Metrics

Accounting frameworks serve as a set of principles that guide the financial reporting process for entities. Generally Accepted Accounting Principles (GAAP) and the International Financial Reporting Standards (IFRS). They are established by the Financial Accounting Standards Board (FASB) in the United States and the International Accounting Standards Board (IASB) internationally, respectively.

Amortization of R&D Costs

This also leads to a direct reduction in retained earnings on the balance sheet. On the cash flow statement, expensed R&D is typically classified as an operating cash outflow, reflecting the immediate use of cash for these activities. It provides a clear, aggregate figure that allows investors and analysts to track R&D spending over time and compare it against other companies. The figure disclosed should represent the total of all costs included under the scope of ASC 730, such as salaries, materials, and depreciation on assets used in R&D. For companies with significant software development activities, the disclosed R&D expense will include costs incurred before technological feasibility is established.

• When it comes to payments made to third parties to perform contract research, only 65% of eligible contract research expenses are included toward the R&D credit, whereas 100% may be eligible for inclusion as a section 174 cost.
• While ASC 730 generally requires expensing R&D costs, there are exceptions for business acquisitions and software development.
• Activities typically included in R&D are laboratory research, the design and testing of prototypes, and the formulation of new product and process designs.
• Federal tax savings are also available for R&D that meets certain criteria.
• Conversely, a stable company might prioritize reporting higher profits and investing in long-term assets, even if it results in higher immediate taxes.
• GAAP requires R&D expenses to be expensed as incurred, with detailed disclosures regarding the types of costs and the nature of the activities.

GAAP and IFRS has direct implications for the balance sheet and income statement. How these costs are accounted for will affect a company’s reported assets, expenses, and ultimately net income. Financial professionals need to understand these frameworks, as they underpin every aspect of financial accounting, from revenue research and development gaap recognition to the treatment of research and development costs. While both standards aim to provide useful information to users of financial statements, their approaches and specific guidelines differ, which can lead to varying treatments of similar transactions. Research and development (R&D) costs refer to expenditures incurred in the process of innovating new products, processes, or services.

If they have no alternative future uses, these items are expensed as acquired or constructed, never depreciated. Similarly, purchased intangibles are amortized into R&D costs over their useful lives if they have alternative future uses but are expensed as incurred if they do not. Additional R&D costs may include salaries, wages, and other personnel costs; contract services; and a reasonable allocation of indirect corporate costs unless they are not clearly related to R&D activities. This contrast has practical implications for how investors view a company’s financial health.

It’s worth noting that the TCJA change to section 174 did not affect the section 41 rules for claiming an R&D tax credit. Delivering KPMG guidance, publications and insights on the application of IFRS® Accounting and Sustainability Standards in the United States. Sharing our expertise to inform your decision-making in an evolving global financial reporting environment. The journey toward convergence of accounting standards has been a proactive and ongoing process. The International Accounting Standards Board (IASB) along with the Financial Accounting Standards Board (FASB) in the United States have consistently worked on aligning accounting principles across borders.

Meanwhile, US GAAP’s approach of expensing can lead to different interpretations of a company’s liquidity. Under U.S. GAAP, research and development (R&D) costs are treated strictly as expenses and are recorded as such when incurred. Once technological feasibility is reached, subsequent costs to get the software ready for sale are capitalized as a software asset. A similar, though distinct, set of rules applies to software developed for internal use. For this type of software, capitalization begins when management authorizes and commits to funding the project, and it is probable that the project will be completed and the software will be used for its intended function.